Tag: bioCSL global influenza vacine industry
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
